AZ505: Potent and Selective SMYD2 Inhibitor for Epigenetic and Cancer Research

Executive Summary: AZ505 is a potent and selective small molecule inhibitor of the protein lysine methyltransferase SMYD2, exhibiting an IC50 of 0.12 μM and high selectivity over related enzymes (IC50 > 83.3 μM for SMYD3, DOT1L, EZH2) [APExBIO Product Page]. It acts via a substrate-competitive mechanism, blocking the peptide substrate binding groove without competing for the SAM cofactor (Chen et al., 2023). AZ505 has been shown to inhibit SMYD2-mediated methylation of histones (H2B, H3, H4) and non-histone proteins such as p53 and Rb, providing a robust tool for epigenetic regulation research. In disease models, pharmacological SMYD2 inhibition by AZ505 reduces fibrosis and inflammation, notably in cisplatin-induced chronic kidney disease models (Chen et al., 2023). Storage, solubility, and workflow considerations are well-defined, supporting reproducible experimental applications.

Biological Rationale

SMYD2 (SET and MYND domain-containing protein 2) is a protein lysine methyltransferase responsible for methylating histones H3 (notably H3K36), H4, and H2B, as well as non-histone substrates including the tumor suppressors p53 and retinoblastoma protein (Rb) (Chen et al., 2023). Histone methylation regulates chromatin structure and gene expression, playing a central role in epigenetic control (APExBIO). Aberrant SMYD2 activity is implicated in cancer, kidney disease, and fibrotic disorders. SMYD2 is overexpressed in gastric cancer and esophageal squamous cell carcinoma (ESCC), correlating with tumor progression and poor prognosis. In chronic kidney disease (CKD), SMYD2 upregulation contributes to renal fibrosis and inflammation, making it a relevant therapeutic target (Chen et al., 2023).

Mechanism of Action of AZ505, a potent and selective SMYD2 inhibitor

AZ505 is a small molecule inhibitor engineered for high affinity and selectivity against SMYD2. It acts as a substrate-competitive inhibitor, binding specifically to the peptide substrate binding groove of SMYD2, thereby blocking access of protein substrates but not interfering with the S-adenosylmethionine (SAM) cofactor binding site (Chen et al., 2023). This mechanism permits targeted inhibition of SMYD2-catalyzed methylation events on both histone and non-histone proteins. The inhibition is characterized by an IC50 of 0.12 μM and a Ki of 0.3 μM under standard assay conditions (in vitro enzymatic assays, pH 7.5, 25°C). AZ505 shows minimal off-target activity, with IC50 values exceeding 83.3 μM for related methyltransferases such as SMYD3, DOT1L, and EZH2 (APExBIO). This selectivity is crucial for dissecting SMYD2-specific pathways and minimizing confounding results in epigenetic regulation research.

Evidence & Benchmarks

• AZ505 inhibits SMYD2 activity with an IC50 of 0.12 μM in biochemical assays (APExBIO, product specs).
• AZ505 demonstrates high selectivity, showing no significant inhibition of SMYD3, DOT1L, or EZH2 at concentrations up to 83.3 μM (APExBIO, product specs).
• In cisplatin-induced CKD mouse models, AZ505 administration reduced SMYD2 expression, improved renal function, and decreased fibrosis and inflammatory cytokines (IL-6, TNF-α) (Chen et al., 2023).
• AZ505 inhibits the expression of epithelial-mesenchymal transition (EMT) and fibrosis-related proteins in tubular epithelial cell cultures exposed to cisplatin (Chen et al., 2023).
• AZ505 does not compete with the SAM cofactor, enabling specific interrogation of substrate interactions with SMYD2 (APExBIO).
• For detailed practical guidance, the article "AZ505, a Potent and Selective SMYD2 Inhibitor: Real-World..." provides experimental tips for reproducibility in cell-based and translational assays, complementing this mechanistic overview (Avacopan Lab).
• For a broader translational context, "AZ505: SMYD2 Inhibitor Unlocks Epigenetic and Fibrotic Pathways" explores advanced disease models and future opportunities beyond standard cancer biology, extending the foundational findings presented here (TCS359).

Applications, Limits & Misconceptions

AZ505 is primarily used as a research tool in the following contexts:

• Epigenetic Regulation Research: Dissecting the roles of SMYD2 in histone methylation and gene expression.
• Cancer Biology Research: Investigating the role of SMYD2 in oncogenic transformation, tumor suppressor modification, and proliferation, especially in gastric cancer and ESCC.
• Fibrosis and Inflammation Models: Studying the contribution of SMYD2 to fibrosis and inflammatory signaling in renal and other tissues (Chen et al., 2023).

For detailed scenario-driven guidance on optimizing protocols and workflow integration, see the complementary resource "AZ505, a Potent and Selective SMYD2 Inhibitor: Data-Driven Laboratory Guidance," which offers best practices for reliable assay results (KDM2A). This article extends those findings by detailing the mechanism and selectivity of AZ505.

Common Pitfalls or Misconceptions

• AZ505 is not a pan-methyltransferase inhibitor; it is highly selective for SMYD2 and has negligible activity on related enzymes at recommended concentrations (APExBIO).
• AZ505 is not suitable for diagnostic or therapeutic use in humans; it is designated for research purposes only (APExBIO).
• Solubility is limited in aqueous buffers; DMSO is the recommended solvent, with warming to 37°C and ultrasonic agitation advised for complete dissolution (APExBIO).
• AZ505 does not inhibit SMYD2 via cofactor (SAM) competition, so studies requiring cofactor competition should use alternative compounds.
• Experimental results may be context-dependent; not all cell types or disease models exhibit the same degree of SMYD2 dependence.

Workflow Integration & Parameters

AZ505 (B1255, APExBIO) is provided as a solid compound. For use, dissolve in DMSO; warming at 37°C and ultrasonic shaking improves solubility. Recommended storage is at -20°C to preserve chemical stability. For cell-based assays, typical working concentrations range from 0.1 μM to 10 μM; always include appropriate DMSO controls. In in vivo models, dosing regimens should be optimized based on pharmacokinetics and toxicity data from published literature. For protocol optimization and troubleshooting, consult "AZ505: A Potent and Selective SMYD2 Inhibitor for Epigene...", which offers scenario-driven workflows and highlights the reproducibility advantages of substrate-competitive inhibition (P53 Tumor Suppressor Fragment). This article clarifies the mechanistic basis of AZ505 use, complementing those practical guides.

Conclusion & Outlook

AZ505, available from APExBIO, is a well-validated, potent, and selective SMYD2 inhibitor with broad utility in epigenetic regulation, cancer biology research, and disease modeling. Its substrate-competitive mechanism and high selectivity profile enable precise dissection of SMYD2-dependent pathways. Published evidence supports its use in models of cancer, fibrosis, and renal injury, with defined protocols for solution preparation and storage. As interest in targeted epigenetic modulation grows, AZ505 will remain a valuable reagent for mechanistic and translational studies. For further technical details and ordering, see the product page.